[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,142,0,25,[9,47,69,99,124,149,187,224,255,289,315,341,367,390,413,434,464,490,516,540,567,587,618,635,659],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100054009","endometriosis-and-migraine-100054009",false,"NCT06785129","Endometriosis and Migraine","Mechanisms Underlying Endometriosis and Migraine Comorbidity","EMC","Inclusion Criteria:\n\n1. Patients with diagnosed endometriosis, migraine, or both endometriosis and migraine\n2. Healthy control subjects with no history of chronic pain\n3. Age 12-45\n4. Assigned female sex at birth\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Presence of prolactinoma\n3. Presence of psychiatric, neurological, endocrinological and\u002For developmental conditions and taking medications for these conditions\n4. Current use of dopamine agonist or SSRI medications\n5. For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health",true,"FEMALE","12 Years","45 Years",{"count":23,"type":24},120,"ESTIMATED","OBSERVATIONAL","This study aims to determine differences in experimental pain and sex hormone levels between patients with migraine, patients with endometriosis, patients with migraine and endometriosis, and healthy controls. Participants will complete surveys, experimental pain paradigms and collection of samples for hormone analyses.",[28,29],"Migraine","Endometriosis",[28,31,32,33],"endometriosis","hormones","pain","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2025-02-12",{"date":42,"type":24},"2030-01-01",{"name":44,"class":45},"Washington University School of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":18,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":63,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":46},"100053991","migraine-in-adolescents-100053991","NCT05654012","Migraine in Adolescents","Inclusion criteria for healthy participants:\n\n1. Age 10-13\n2. Males or females (biological sex)\n3. Not diagnosed with migraine or having migraine symptoms\n4. With a first degree relative diagnosed with migraine (for the Fam-His group) or without a first or a second degree relative diagnosed with migraine (for the No-Fam-His group)\n\nInclusion criteria for participants with migraine:\n\n1. Age 10-13\n2. Males or females (biological sex)\n3. Diagnosed with migraine or having migraine symptoms\n4. Migraine duration \\> 6 months\n5. Without preventative treatment or with stable preventative treatment for migraine (no change in intervention in the last 6 months)\n\nExclusion Criteria for the healthy group:\n\n* Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:\n\n  1. Diagnosis of any chronic pain syndrome\n  2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder\n  3. Taking pain or psychiatric medications regularly\n  4. Having an MRI contraindication such as metal in the body or claustrophobia\n  5. Not able to understand and communicate in English\n\n     Exclusion Criteria for the migraine group\n* Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:\n\n  1. Diagnosis of any chronic pain syndrome other than migraine\n  2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder\n  3. Having an MRI contraindication such as metal in the body or claustrophobia\n  4. Not able to understand and communicate in English","ALL","10 Years","13 Years",{"count":57,"type":24},250,"INTERVENTIONAL",[60],"NA","Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents\n\nAim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset.\n\nAim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset.\n\nAim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.",[28],{"date":37,"type":38},{"date":65,"type":38},"2023-06-01",{"date":67,"type":24},"2030-03-15",{"name":44,"class":45},{"id":70,"slug":71,"hasResults":12,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":18,"sex":53,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":58,"phases":79,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":46},"100053714","early-phase-1-mechanistic-studies-of-psilocybin-in-headache-disorders-100053714","NCT06464367","Mechanistic Studies of Psilocybin in Headache Disorders","Inclusion criteria:\n\n* Age 21 to 70 (inclusive)\n* Migraine disease per ICHD-3 criteria (for migraine participants) OR Healthy control patient\n\nExclusion criterion\n\n* Unstable medical condition or serious nervous system pathology\n* Pregnant, breastfeeding, lack of adequate birth control\n* Psychotic or manic disorder\n* Substance abuse in the prior 3 months\n* Use of classic psychedelics (e.g., psilocybin, LSD, mescaline) in the past 6 months\n* Use of cannabis or other THC products in the prior 2 weeks\n* Urine toxicology positive to drugs of abuse\n* The use of triptans (e.g., sumatriptan) or ditans (e.g., lasmiditan) more than twice weekly on average\n* Use of serotonergic preventive therapies (i.e., taken chronically; amitriptyline, fluoxetine, imipramine, cyproheptadine) in the past 6 weeks\n* Use of preventive or transitional treatments that produce spikes and waning of symptom relief (e.g., botulinum toxin, calcitonin gene-related peptide system targeting antibodies, peripheral nerve or ganglion blocks, chiropractic manipulation)\n* History of a bleeding disorder or are currently taking anticoagulants (e.g., warfarin, enoxaparin, dabigatran, apixaban).\n* Use of non-steroidal anti-inflammatory drugs (NSAIDs; e.g., ibuprofen, naproxen) in the 7 days before PET scan and 7 days after PET scan.","21 Years","70 Years",{"count":78,"type":24},50,[80],"EARLY_PHASE1","In previous clinical trial work, the investigators observed lasting reductions in headache burden after limited dosing of psilocybin. This purpose of this study is to examine potential sources for this observed effect. This study will measure brain resting state functional connectivity (fMRI), central synaptic density (SV2A PET), peripheral markers of inflammation, circadian rhythm (actigraphy), and sleep (sleep EEG) in both migraine and healthy control participants before and one week after the administration of psilocybin or an active control agent.",[28],[84,85,86,87,88,89,90],"psilocybin","resting state functional connectivity","synaptic density","synaptic vessel glycoprotein 2A (SV2A)","circadian rhythm","sleep","inflammation","2026-07-09",{"date":37,"type":38},{"date":94,"type":38},"2025-05-19",{"date":96,"type":24},"2027-12-31",{"name":98,"class":45},"Yale University",{"id":100,"slug":101,"hasResults":12,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":58,"phases":108,"briefSummary":109,"conditions":110,"keywords":111,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":4},"100053748","headache-diary-for-migraine-patients-100053748","NCT07698249","Headache Diary for Migraine Patients","Use of a Headache Calendar\u002FJournal in Patients Who Have Migraine","Inclusion Criteria:\n\n* Adults diagnosed with migraine (episodic or chronic) according to ICHD-3 criteria, with at least 3 months of confirmed diagnosis. Both episodic migraine (≤14 headache days\u002Fmonth) and chronic migraine (≥15 headache days\u002Fmonth) are eligible and will be recorded as a demographic subgroup variable.\n\nExclusion Criteria:\n\n* Individuals under the age of 18\n* Non-English speaking individuals","18 Years",{"count":78,"type":24},[60],"Use of a headache journal\u002Fcalendar in patients who have migraine to ascertain if keeping a headache journal affects the quality of life and the headache burden.",[28],[112,113,114],"migraine","diary","calendar","NOT_YET_RECRUITING","2026-07-07",{"date":37,"type":38},{"date":119,"type":24},"2026-08-01",{"date":121,"type":24},"2029-08-01",{"name":123,"class":45},"Hackensack Meridian Health",{"id":125,"slug":126,"hasResults":12,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":58,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":148},"100642179","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-elismetrep-k-304-in-the-acute-treatment-of-migraine-100642179","NCT07645924","A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine","A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Acute Treatment of Migraine","Inclusion Criteria:\n\n1\\. Be a male or female, age 18 to 75 years, inclusive, at the time of signing informed consent. 2. Has greater than a one-year history of migraine with or without aura as defined by International Headache Society criteria 1.1 and 1.2 and his\u002Fher migraines typically last between 4 to 72 hours, if untreated. 3. Has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the 2 months prior to screening (Visit 1). 4. Meet the following requirements:\n\na. Is a male OR b. Is a female who is of non-childbearing potential defined by at least one of the following criteria: i. Postmenopausal as defined by one of the following:\n\n1. A minimum of 12 months of spontaneous amenorrhea or\n2. A minimum of 6 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone level \\> 40 mIU\u002FmL or\n3. At least 6 weeks post bilateral oophorectomy (with or without hysterectomy). OR ii. Post hysterectomy or bilateral salpingectomy, based on the participant's recall of their medical history OR c. Is a female of reproductive potential and: i. Agrees to remain abstinent from heterosexual activity OR ii. Agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the End of Study visit.\n\nAcceptable methods of birth control are:\n\n1. Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, or transdermal).\n2. Progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; or implantable).\n3. Intrauterine device (IUD);\n4. Intrauterine hormone-releasing system (IUS);\n5. Bilateral tubal occlusion;\n6. Vasectomized partner;\n7. Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action;\n8. Male or female condom with or without spermicide;\n9. Cap, diaphragm or sponge with spermicide; a combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods).\n\n5\\. Voluntarily agrees to participate in the study by giving written informed consent. 6. Is able to read, understand and complete the study questionnaires and eDiary. 7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions. 8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.\n\nExclusion Criteria:\n\nParticipants are excluded from the trial if any of the following criteria apply:\n\n1. Is a female who is pregnant, breast-feeding, or intends to become pregnant during the planned course of the trial.\n\n   Migraine history-related\n2. Has difficulty distinguishing his\u002Fher migraine attacks from tension-type headaches.\n3. Has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours.\n4. Has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the 3 months prior to screening (Visit 1).\n5. Has brainstem (also known as basilar-type) or hemiplegic migraine headache, or retinal migraine.\n6. Was \\>50 years old at age of first migraine onset.\n7. Is taking migraine prophylactic medication where the prescribed dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.\n\n   Medical history related\n8. Has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia, or significant neurological disorders other than migraine \\[Patients who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study\\].\n9. Is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Patients must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.\n10. Has a recent history (within the past 3 years of the screening visit) or current diagnosis or evidence of endocrine, hematological, immunological (including Sjogren's syndrome), renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases or hepatic impairment that, per the investigator's judgement, may jeopardize the subject's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and\u002For safety results.\n11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.\n12. Has a history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Patients with myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, cardiac surgery, stroke or transient ischemic attack during the 6 months prior to screening.\n13. Has a history of human immunodeficiency virus disease.\n14. Has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.\n\n    Laboratory, vital sign, and electrocardiogram related\n15. Has a positive test result at screening for hepatitis B surface antigen, hepatitis C virus antibody.\n16. Has a screening estimated glomerular filtration rate estimated with the Modification of Diet in Renal Disease (MDRD) equation of \\\u003C30 mL\u002Fmin\u002F1.73 m2.\n17. Has a screening result for alanine aminotransferase or aspartate aminotransferase of \\>2.0 X upper limit of normal (ULN) or total bilirubin \\>1.5 X ULN at the Screening visit. Note: An isolated bilirubin \\>1.5 X ULN is acceptable if bilirubin is fractionated and direct bilirubin is within the laboratory normal range.\n18. Has a mean value for triplicate corrected QT interval to Fridericia's formula (QTcF) \\>450 ms for males and \\>470 ms for females at screening.\n19. Has a mean value for triplicate seated systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>95 mmHg measured after at least 5 minutes at rest at the Screening Visit. Note: If a participant's blood pressure is exclusionary on the first triplicate assessment at the Screening Visit, they may have one repeat triplicate blood pressure assessment at that visit after another rest of at least 10 minutes.\n\n    Medication use and substance abuse related\n20. Has known history of or suspected abuse of alcohol or recreational drugs at Screening.\n21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol \\[THC\\] or cannabidiol \\[CBD\\] within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics\u002Fopiates) within 6 months prior to screening.\n22. Has a positive drug screen at screening. Note:\n\n    1. If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g., for insomnia) and confirmatory documentation is obtained from the prescribing physician.\n    2. If amphetamines are detected on the drug screen, this is not exclusionary if the participant is taking a stimulant medication for a therapeutic purpose (e.g., Adderall for attention deficit hyperactivity disorder), confirmatory documentation is obtained from the prescribing physician, and the stimulant medication in question is known to be detected as amphetamine on the drug screen being used.\n23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation (detailed in the protocol).\n24. Has any use of prescription opiate medications within 14 days of screening or any anticipated\u002Fpotential use of opiates during study participation.\n25. Has a history of use of ergotamine medications ≥10 days per month on a regular basis for ≥3 months prior to screening.\n26. Has a history of non-narcotic analgesic intake ≥15 days per month for\n\n    * 3 months prior to screening.\n\n    Other\n27. Has known or suspected hypersensitivity to trial product(s) or related products.\n28. Has a history of multiple significant and\u002For any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.\n29. Has any surgery scheduled for the duration of the trial.\n30. Has a screening hemoglobin \\\u003C11.0 g\u002FdL (males) or \\\u003C10.0 g\u002FdL (females) or has a known hemoglobinopathy (e.g., sickle cell anemia, hemolytic anemia).\n31. Has previous participation in this trial. Participation is defined as signed informed consent.\n32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g., antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening or ever signed an informed consent for Study K-304 P004. Note: Patients may not be screened at more than one trial site for this study.\n33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and\u002For safety results.\n34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.","75 Years",{"count":133,"type":24},1800,[135],"PHASE3","This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with placebo, in the acute treatment of migraine.",[28],"2026-06-30",{"date":140,"type":38},"2026-07-02",{"date":142,"type":24},"2026-07",{"date":144,"type":24},"2027-02",{"name":146,"class":147},"Kallyope Inc.","INDUSTRY",115,{"id":150,"slug":151,"hasResults":12,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":155,"eligibilityCriteria":156,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":157,"enrollmentInfo":158,"targetDuration":160,"studyType":25,"phases":4,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":184,"locationsCount":186},"100551404","study-for-prevent-chronification-migraine-through-prediction-of-response-to-treatment-with-anti-cgrp-antibodies-100551404","NCT06459648","Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies","Prediction Study or Response to Treatment With Anti-CGRP Monoclonal Antibodies in Migraine","PREDI-CGRP","Inclusion Criteria:\n\n* Patients aged between 18 and 65 years.\n* Caucasian ethnicity.\n* Patients diagnosed with migraine with and without high-frequency episodic aura (more than 8 days of migraine per month) or chronic by a neurologist expert in headaches and according to the criteria proposed in the International Classification of Headache Diseases, 3rd edition (ICHD- 3).\n* Have at least one year of history of migraine.\n* Patients must maintain stable preventive treatment in the previous month and not have received botulinum toxin in the month prior to starting the monoclonal antibody.\n* Patients able to describe their clinical situation and the characteristics of their headache.\n* Grant your informed consent.\n\nExclusion Criteria:\n\n* Patients who present with another type of non-migraine headache, with the exception of headache due to excessive use of analgesic medication.\n* Neurological focus in the examination.\n* Pregnancy or breastfeeding period.\n* Patients with cognitive deficiency or pathology that may prevent or hinder the correct completion of the study.\n* Patients who require changes in preventive treatment during the first 6 months after starting treatment with monoclonal antibodies.\n* Patients who present any significant adverse effect that requires withdrawal or change of anti-CGRP drug.","65 Years",{"count":159,"type":24},350,"18 Months","Being able to predict each patients response to a specific treatment can mean a significant improvement in socioeconomic costs, but above all in their quality of life. With the present study, the investigators aim to analyze in a combined way different clinical, biological and neuroimaging variables, which allow the clinical staff to anticipate the response to treatment with anti-CGRP monoclonal antibodies in patients with migraine.",[28],[28,164,165,166,167,168,169,170,171,172,173,174,175,176,177,178,179],"headache","antibodies","antibody","monoclonal antibody","anti-cgrp","anti cgrp","cgrp","prediction","treatmen","migraine treatment","treatment with anti-CGRP monoclonal antibodies","anti-cgrp antibodies","anti-cgrp antibody","anti-cgrp monoclonal antibodies","migraine and antibodies","migraine and cgrp",{"date":140,"type":38},{"date":182,"type":38},"2023-04-26",{"date":142,"type":24},{"name":185,"class":45},"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa",7,{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":18,"sex":53,"minAge":106,"maxAge":157,"enrollmentInfo":195,"targetDuration":197,"studyType":25,"phases":4,"briefSummary":198,"conditions":199,"keywords":204,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":46},"100551403","migraine-attack-pain-phase-prediction-study-100551403","NCT06459635","Migraine Attack Pain Phase Prediction Study","Prediction Study of the Pain Phase of Migraine Attacks in Patients With Episodic Migraine","PREDI-CRISIS","Inclusion Criteria:\n\n* Age between 15 years and 69 years.\n* Diagnosed with migraine by a headache neurologist and according to the criteria proposed by ICHD-3.\n* History of migraine of at least 1 year of evolution.\n* Normal neurological examination.\n* Have given your informed consent.\n* Be able to describe your clinical situation and the characteristics of your headache.\n* Have an average of 10 to 14 migraine days per month in the three months prior to inclusion (high-frequency episodic migraine).\n* User-level management capacity of \"smartphone\" type electronic devices.\n* Be able to complete two months of study follow-up.\n\nExclusion Criteria:\n\n* Presence of another type of headache, with the exception of headache due to excessive use of analgesic medication.\n* Cognitive deficiency or any other pathology that may prevent or make it difficult for the patient to perform the study correctly.\n* Neurological focus in the examination.\n* Pregnancy or breastfeeding period.\n* Patients with known heart disease or bronchopathy, Sjögren\\'s syndrome, diabetes mellitus, or hypo\u002Fhyperthyroidism.\n* Carriers of pacemakers, neurostimulators or any other electronic device that is considered to make the interpretation of biometric records difficult.\n* Anatomical problem that makes the use of the device impossible.\n* Patients in whom it is expected that a change in migraine preventive treatment or other usual treatment will be possible during the study period.",{"count":196,"type":24},70,"2 Months","The study of the ability to predict pain in a migraine attack, through premonitory symptoms and through an ambulatory monitoring device through real-time recording of hemodynamic variables, is one of the strategic lines of research of the unit. of Headaches at the Hospital de La Princesa since 2013 together with the Complutense and Polytechnic University of Madrid. Their results have been reflected in various publications (Pagán J, et al. Sensors 2015; Gago-Veiga AB, et al. J Pain Res 2018) and have promoted the creation of several invention patents.",[28,200,201,202,203],"Migraine Headache","Migraine Disorders","Migraine Without Aura","Migraine With Aura",[28,205,206,207,208,209,210,211,212,213,214,215,216,217,218],"Headache","Predict","Prediction","headache prediction","predict headache","migraine prediction","predict migraine","migraine attacks","migraine attack","headache attack","migraine attack prediction","predict migraine attack","prediction algorithm","algorithm",{"date":140,"type":38},{"date":221,"type":38},"2023-10-09",{"date":142,"type":24},{"name":185,"class":45},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":53,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":58,"phases":235,"briefSummary":236,"conditions":237,"keywords":238,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":254},"100451276","phase-3-efficacy-and-safety-study-of-rimegepant-for-the-preventative-treatment-of-migraine-in-pediatric-subjects-100451276","NCT05156398","Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects","A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention in Children and Adolescents ≥ 6 to \u003C18 Years of Age","Inclusion Criteria:\n\n1. Subject has at least a 6 month history of migraine (with or without aura) and including the following:\n\n   1. 14 or less headache days per month during the 3 month period prior to the Screening Visit\n   2. 6 or more migraine days during the Observation Period\n   3. 14 or less headache days during the Observation Period\n   4. Pediatric Migraine Disability Assessment Scale (PedMIDAS) Disability Score of \\>10 to ≤50, indicating mild (score of 11 to 30) or moderate (score of 31 to 50) disruption in daily activities, as assessed at the Baseline (Randomization) Visit\n   5. Ability to verbally distinguish migraine attacks from tension\u002Fcluster or other types of headaches\n   6. Migraine attacks, on average, lasting 4 - 72 hours if untreated\n   7. Subjects on prophylactic migraine medication are permitted to remain on therapy if the dose has been stable for at least 3 months (12 weeks) prior to the Screening Phase, and the dose is not expected to change during the course of the study. 2) Male and female subjects ≥ 6 to \\\u003C18 years; subjects must be less than 18 at the time of signing assent \u002F consent.\n\n      3)Subjects must have a weight of ≥40 kg (child cohort requirement ≥15 kg) at the Screening Visit.\n\nExclusion Criteria:\n\n1. Subjects with a history of basilar migraine, cluster headaches, or hemiplegic migraine\n2. The subject has a continuous migraine (defined as an unrelenting headache) within 1 month prior to Screening Visit.\n3. The subject has a history or diagnosis of complications of migraine\n4. The subject has a confounding and clinically significant pain syndrome that may interfere with the subject's ability to participate in this study.\n5. The subject has any current psychiatric condition that is uncontrolled and\u002For untreated for a minimum of 6 months prior to the Screening Visit. Subjects with a lifetime history of psychosis and\u002For mania are excluded.\n6. History of suicidal behavior or the subject is at risk of self-harm or harm to others.\n7. History of major psychiatric disorder.\n8. The subject has a current diagnosis or history of substance abuse\n9. The subject has a history of moderate or severe head trauma or other neurological disorder (including seizure disorder) or systemic medical disease that is, in the investigator's opinion, likely to affect central nervous system functioning.","6 Years","17 Years",{"count":234,"type":24},640,[135],"The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to \\\u003C18 years with episodic migraine.",[28],[28,239,240,241,242,243,244],"Migraine prevention","Phonophobia","Photophobia","Nausea","Pediatric migraine","Adolescent migraine","2026-06-29",{"date":247,"type":38},"2026-07-01",{"date":249,"type":38},"2022-02-28",{"date":251,"type":24},"2032-11-27",{"name":253,"class":147},"Pfizer",91,{"id":256,"slug":257,"hasResults":12,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":262,"enrollmentInfo":263,"targetDuration":4,"studyType":58,"phases":265,"briefSummary":267,"conditions":268,"keywords":269,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":288},"100638197","phase-2-study-of-evo756-in-adults-with-migraine-100638197","NCT07616128","Study of EVO756 in Adults With Migraine","A Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of EVO756 for the Prevention of Migraine in Adults","Key Inclusion Criteria:\n\n* Adults aged 18 to \\\u003C65 years\n* Migraine with or without aura, per ICHD-3 criteria\n* History of failure with prior preventive migraine treatments\n* Not currently using migraine preventive therapy\n\nKey Exclusion Criteria:\n\n* Difficulty distinguishing migraine from other headache types or presence of other primary headache disorders\n* Use of certain medications\n* Any clinically significant medical, psychiatric, neurological, cardiovascular, or laboratory abnormalities","64 Years",{"count":264,"type":24},330,[266],"PHASE2","This study will evaluate the efficacy and safety of EVO756 against placebo in adults with migraine.",[28],[270,271,201,200,272,28,273,274,275,203,276,277,202,278,279],"Migraine Disease","Migraine Disorder","Migraine Headaches","Migraines","Migraine in Adults","Migraine Prophylaxis","Migraine With or Without Aura","Migraine With and Without Aura","Episodic Migraine Headache","Chronic Migraine Headache","2026-06-28",{"date":247,"type":38},{"date":283,"type":24},"2026-06",{"date":285,"type":24},"2027-11",{"name":287,"class":147},"Evommune, Inc.",14,{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":12,"sex":19,"minAge":106,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":58,"phases":299,"briefSummary":300,"conditions":301,"keywords":302,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":314},"100548190","phase-3-study-of-oral-ubrogepant-to-assess-adverse-events-and-change-in-disease-activity-in-adult-participants-with-menstrual-migraine-100548190","NCT06417775","Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension","UBRO MM","Inclusion Criteria:\n\n* At least a 1-year history of migraine with or without aura.\n* Have experienced migraine attacks in at least 2 of 3 perimenstrual periods (PMPs) during the screening period.\n* Collection of daily eDiary data for 3 perimenstrual periods during the up to 16-week screening period to confirm a menstrual migraine (MM) diagnosis.\n* Have regular menstrual cycles of between 21-35 days in length.\n* Less than 15 headache days per month.\n* At least 70% compliance completing screening period and at least 3 out of 5 days of ediary data in each of 3 screening PMP.\n\nExclusion Criteria:\n\n* History of migraine with brainstem aura, hemiplegic migraine, or retinal migraine.\n* Clinically significant history of cardiovascular or cerebrovascular disease per the investigator's opinion.\n* Clinically significant abnormalities in the physical examination as determined by the investigator.\n* Clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, gynecological, or neurologic disease per the investigator's opinion.\n* Acute headache medication overuse.",{"count":298,"type":24},496,[135],"A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. Menstrual migraine (MM) is defined as migraine attacks that occur within the perimenstrual period (PMP) in at least 2 out of 3 menstrual cycles. The PMP is from 2 days before the onset of menstrual bleeding to 2 days after. This study will assess how safe and effective ubrogepant is in treating menstrual migraine. Adverse Events and change in disease activity will be assessed.\n\nUbrogepant is an investigational drug being developed for short-term prevention of menstrual migraine. Participants will be randomly assigned to one of the 2 groups to receive either ubrogepant or placebo. Around 496 adult female participants with menstrual migraine will be enrolled in approximately 100 sites in the United States and Puerto Rico.\n\nParticipants will receive oral ubrogepant tablets once daily for 7 consecutive days starting 3 days prior to estimated onset of menses per cycle for 3 PMPs during double-blind period (16 weeks). Eligible participants may continue to receive oral ubrogepant tablets once daily for 7 consecutive days per cycle starting 3 days prior to estimated onset of menses during open-label extension period (52 weeks).\n\nThere may be higher treatment burden for participants in this trial compared to their standard of care. Participants will collect data daily in electronic diaries and attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.",[28],[28,303,304,305],"Menstrual Migraine","Ubrogepant","UBRELVY","2026-06-26",{"date":138,"type":38},{"date":309,"type":38},"2024-09-10",{"date":311,"type":24},"2027-09",{"name":313,"class":147},"AbbVie",106,{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":157,"enrollmentInfo":323,"targetDuration":325,"studyType":25,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":46},"100645361","chronology-and-sequence-of-premonitory-symptoms-100645361","NCT07681466","Chronology and Sequence of Premonitory Symptoms","Chronology and Sequence of Premonitory Symptoms to Understand How Migraine Attack Starts: the CHRONOpS Study","CHRONOpS","Inclusion Criteria:\n\n* Diagnosis of episodic (EM) or chronic migraine (CM) or CM with medication overuse headache (MOH) according to ICHD-III criteria;\n* Age between 18 and 65 years;\n* At least 2 migraine days (MMD) in the month preceding the inclusion;\n* Migraine history of at least 12 months prior to inclusion\n* Signed written informed consent.\n\nExclusion Criteria:\n\n* History or current diagnosis of secondary headache disorders as defined by ICHD-III;\n* History of other neurological comorbidities or major psychiatric disorders;\n* History of migraine for \\\u003C 12 months prior to the inclusion;\n* Opioid overuse according to the ICHD-III criteria;\n* Pregnancy or breastfeeding.",{"count":324,"type":24},500,"6 Months","The purpose of this study is to prospectively investigate the temporal sequence of premonitory symptoms across multiple migraine attacks.",[28],[329,330,331,332,333],"premonitory symptoms","sequence","hypothalamus","chronology","disability","2026-06-25",{"date":140,"type":38},{"date":337,"type":38},"2026-03-17",{"date":311,"type":24},{"name":340,"class":45},"University of Roma La Sapienza",{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":76,"enrollmentInfo":348,"targetDuration":4,"studyType":58,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":360,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":46},"100644516","multimodal-physiotherapy-intervention-for-people-with-migraine-100644516","NCT07671703","Multimodal Physiotherapy Intervention for People With Migraine","What is the Effectiveness of an Evidence-based Multimodal Intervention When Compared With Conventional Physiotherapy, and Which Factors Determine Treatment Success in Patients With Migraine- a Pilot Study","Inclusion Criteria\n\n* Aged 18-70 years.\n* Have a diagnosis of migraine established by a headache specialist according to the International Classification of Headache Disorders, 3rd edition (ICHD-3).\n* Have experienced migraine symptoms for more than 3 months, with headaches occurring on at least 2 days per month.\n* Provide written informed consent before participation.\n* Complete a study-specific self-assessment questionnaire based on the ICHD-3 criteria to confirm the migraine diagnosis and classify participants as having episodic or chronic migraine.\n\nExclusion Criteria\n\n* Other primary or secondary headache disorders.\n* Acute neurological diseases or abnormal neurological examination findings.\n* Rheumatic diseases, vascular diseases, cancer, or other serious medical conditions.\n* Comorbid chronic pain disorders (e.g., fibromyalgia).\n* Diagnosed psychiatric disorders (e.g., major depression or schizophrenia).\n* Substance abuse.\n* Physiotherapy for headache or neck pain within 3 months before study enrolment.\n* Previous surgery involving the jaw, cervical spine, or head.\n* Pregnancy.\n* Pain not clearly attributable to migraine.\n* Inability or unwillingness to provide informed consent.\n* There are no restrictions regarding sex, ethnicity, or country of residence.",{"count":349,"type":24},195,[60],"Migraine is one of the most prevalent primary headache disorders worldwide and is associated with substantial impairments in quality of life, work productivity, and psychosocial functioning. In Germany alone, nearly 18 million people are affected. Although pharmacological therapy remains a cornerstone of migraine management, non-pharmacological interventions-particularly physiotherapy-play an important role in multimodal treatment concepts and are generally well tolerated.\n\nRecent evidence suggests that physiotherapy for migraine should extend beyond conventional manual techniques and include patient education, aerobic endurance training, and self-management strategies. However, in routine clinical practice, physiotherapeutic approaches vary widely and are often not fully aligned with current evidence-based recommendations. Moreover, there is a lack of pragmatic randomized controlled studies evaluating the effectiveness of structured, evidence-based multimodal physiotherapy compared with conventional physiotherapy under real-world clinical conditions.\n\nThis study is a randomized controlled pilot trial designed to compare an evidence-based multimodal physiotherapeutic intervention with conventional physiotherapy in adult patients with migraine. The multimodal intervention consists of evidence-based physiotherapy, structured patient education on migraine and pain mechanisms, guided moderate aerobic endurance training, and relaxation techniques. The control group receives conventional physiotherapy according to German standard clinical practice.\n\nThe study is designed as a randomized controlled trial with a pre-post design. Adult patients aged 18 to 60 years with a specialist-confirmed diagnosis of migraine will be recruited from a specialized pain therapy center in Osnabrück, Germany. Participants will be randomly allocated to either the multimodal treatment group or the usual care physiotherapy group. The intervention period lasts three months.\n\nThe primary outcome is migraine-related quality of life measured using the Headache Impact Test (HIT-6™). Secondary outcomes include headache frequency and intensity assessed via headache diaries, migraine-related work absenteeism, and functional impairment. Feasibility outcomes will be evaluated through the feasibility and acceptance of the multimodal treatment program from the perspective of the treating physiotherapists.\n\nThe results are expected to provide robust evidence on the effectiveness and real-world applicability of multimodal treatment programs compared with usual care for migraine management in Germany.\n\nEmbedded to this project there is also the prediction analysis. For that patients will be divided into those who responded to the treatment and those who stay stable or get worse after treatment. Based on that a statistical analysis will be used to assess which factors influenced the improvement of those patients after physical therapy treatment.",[28],[28,354,355,356,357,358,359],"Pain education","Aerobic exercises","Relaxation training","Manual therapy","Localized exercises","Prediction of success",{"date":306,"type":38},{"date":362,"type":38},"2026-02-11",{"date":364,"type":24},"2028-12-31",{"name":366,"class":45},"Hochschule Osnabruck",{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":76,"enrollmentInfo":374,"targetDuration":4,"studyType":58,"phases":376,"briefSummary":378,"conditions":379,"keywords":380,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":389},"100590794","phase-4-comparative-effectiveness-of-migraine-preventive-medications-the-apt-comparison-study-100590794","NCT06972056","Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study","A Comparative Effectiveness Study of Oral Medications Used for Migraine Prevention: The APT Comparison Study","Inclusion Criteria:\n\n* Adults, 18-70 years of age at the time of enrollment\n* Migraine with aura, migraine without aura, and\u002For chronic migraine; according to ICHD-3 diagnostic criteria. (Those with daily or continuous headaches are not excluded.)\n* Migraine onset prior to 50 years of age\n* Migraine present for at least 12 months at the time of enrollment\n* At least four \"moderate to severe headache days\" per month (by patient self-report and then confirmed during four-week pre-randomization headache diary phase) A \"moderate to severe headache day\" is defined as a day during which there is a headache of moderate to severe intensity that lasts for at least four hours, or a day on which a migraine-specific acute medication is taken to treat headache.\n* If already taking a migraine preventive treatment, willing to continue with that treatment without dose change during the first 16 weeks of the study, including the 4-week run-in phase and 12-week randomized phase.\n* Not pregnant or breastfeeding\n* Women of childbearing potential must agree to use effective methods of contraception to reduce the risk of pregnancy.\n* Willingness and ability to provide informed consent.\n* Willingness and ability to complete all research visits.\n\nExclusion Criteria:\n\n* Contraindications to taking atogepant, propranolol, or topiramate.\n* Currently taking atogepant, propranolol, or topiramate\\*\n* Previously took atogepant, propranolol, or topiramate\\*\n* Unwillingness to take atogepant, topiramate, or propranolol.\n* Current use of a CGRP-targeting preventive medication or beta-blocker\n* Migraine with brainstem aura\n* Hemiplegic migraine\n* Retinal migraine\n* Migraine aura without headache (exclusively)\n* Pure menstrual migraine\n* Trigeminal autonomic cephalalgias\n* Facial neuralgias\n* Secondary headache disorders (medication overuse headache is not an exclusion)\n* Migraine preventive treatment has been started or dose has been changed within 12 weeks prior to potential enrollment.\n* Used opioids or butalbital on five or more days per month on average for at least 3 months prior to enrollment.\n* Current or past epilepsy\n* Severe hepatic impairment\n* Moderate or more severe renal impairment \\* Occasional as needed use of propranolol, currently or in the past, is not an exclusion, such as taking as needed propranolol for treatment of anxiety.",{"count":375,"type":24},1335,[377],"PHASE4","This goal of this study is to compare three medications used for migraine preventive treatment.\n\nThis study will compare atogepant, a newer migraine preventive medication, with two older preventive medications, topiramate and propranolol. It will be determined if one works better and is more tolerable than the others.\n\nResearch participants will:\n\n* Be randomly assigned to one of the three medications.\n* Provide information about their migraine pattern using a daily headache diary and during research visits.",[28],[28,381,239],"Migraine with aura",{"date":245,"type":38},{"date":384,"type":38},"2025-07-09",{"date":386,"type":24},"2029-12-01",{"name":388,"class":45},"Mayo Clinic",35,{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":58,"phases":400,"briefSummary":401,"conditions":402,"keywords":403,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":46},"100578202","cocoa-extract-for-migraine-trial-100578202","NCT06808230","Cocoa Extract for Migraine Trial","Cocoa Flavanols for Migraine: A Pilot Study","CORAL","Inclusion Criteria:\n\n* Women and men aged ≥18 years\n* Self-reported clinician diagnosis of migraine with or without aura which does not meet criteria for chronic migraine (according to the International Classification of Headache Disorders 3rd edition)\n\n  * Individuals with self-reported migraine will need to report a clinician diagnosis of migraine and be classified as having migraine or probable migraine by the American Migraine Study (AMS) migraine screener. The AMS migraine screener, which has a sensitivity of 100% and a specificity of 82% for the diagnosis of migraine will be used to confirm self-reported migraine status.\n  * History of migraine dating for at least one year\n* Self-report of 4 to 14 migraine attacks during the 30 days prior to enrollment in the study\n* Completion of at least 22 headache diary days during the 28 day run-in period\n\n  o Report migraine frequency between 4 to 14 days during the 28 day run-in period\n* If currently using medications to prevent or treat migraine, no new medication use within the past 3 months\n* No new use of behavioral interventions within the past 3 months and\u002For agree to not begin new behavioral interventions during this trial\n* Be willing to complete all study procedures and be randomized to all interventional groups\n* Be fluent in English\n* Own an iPhone or Android device and be willing to download MyCap to the device\n\nExclusion Criteria:\n\n* Self-reported history of stroke or transient ischemic attack; history of brain surgery or spine surgery; currently receiving treatment for a concussion; and self-reported diagnosis of cluster headache, brain tumor, brain aneurysm, traumatic brain injury, multiple sclerosis, epilepsy, schizophrenia, or bipolar disorder\n* Kidney failure or current dialysis treatment or any medical condition which the participant believes could lead to difficulty complying with the protocol\n* Current alcohol or substance abuse (self-reported)\n* Self-reported clinician diagnosis of medication overuse headache\n* Currently or recently (past 6 months) received Botox treatment for migraine\n* Failure to return the baseline urine sample\n* Currently pregnant, nursing, or intending to become pregnant during the study period.\n* Unwilling to forgo use of out-of-study supplements of cocoa extract during the trial\n* Extreme sensitivity to caffeine",{"count":399,"type":24},114,[60],"The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are:\n\n* Will we be able to enroll 114 participants during the recruitment period?\n* Will participants take study pills daily during the pill-taking period?\n\nResearchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population.\n\nParticipants will be asked to:\n\n* Provide two urine samples\n* Complete daily questionnaires\n* Take four study pills a day for 12 weeks",[28],[112,404,405],"cocoa extract","cocoa flavanol",{"date":245,"type":38},{"date":408,"type":38},"2025-06-23",{"date":410,"type":24},"2026-12-01",{"name":412,"class":45},"Brigham and Women's Hospital",{"id":414,"slug":415,"hasResults":12,"nctId":416,"briefTitle":417,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":18,"sex":53,"minAge":106,"maxAge":4,"enrollmentInfo":420,"targetDuration":4,"studyType":58,"phases":422,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":430,"leadSponsor":432,"locationsCount":46},"100643927","phase-1-a-prospective-open-label-study-evaluating-the-effectiveness-of-gepants-for-acute-treatment-of-migraine-in-the-emergency-department-100643927","NCT07667621","A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department","A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department","Inclusion Criteria:\n\n* • At least 18 years of age\n\n  * Capacity to provide informed consent (without a Representative)\n  * Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is \\>72 hours. Must have been headache free for \\>48 hours prior to current attack.\n  * Willing to participate in post-discharge telephone assessments\n  * English and\u002For Spanish speaking patients\n\nExclusion Criteria:\n\n* • Use of intranasal decongestants within 1 hour prior to study drug administration, due to the potential to decrease absorption of intranasal zavegepant.\n\n  * Use of analgesics or abortive headache medications within 60 minutes of study medication administration\n  * Use of the following drug\u002Ffood categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors\u002Finducers, 5) NTCP transporter potent inhibitors\u002Finducers\n  * History of ischemic cardiovascular disease, diabetes, or hypertension (diagnosed or likely based on multiple readings), that was recently diagnosed within 3 months of screening or is currently uncontrolled or unstable\n  * History of any stroke within 3 months, or any lifetime stroke and age ≥65 years\n  * History of significant peripheral vascular disease, as assessed by the investigator or qualified delegate\n  * History of Raynaud's Phenomenon (medically diagnosed, or non-medically diagnosed with affirmative responses to both unusual sensitivity and finger color change with cold exposure)\n  * History of severe hepatic impairment, as assessed by the investigator or qualified delegate\n  * History of kidney disease stage 4 (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n  * History of hypersensitivity reaction to rimegepant, zavegepant, or to any included inactive ingredients\n  * Lifetime use of CGRP-targeting acute or preventive migraine medications\n  * In custody of law enforcement\n  * Current pregnancy or lactation\n\n    * All individuals of childbearing potential must have a negative pregnancy test at screening (urine or serum).\n    * A person is considered to be of childbearing potential if possessing female reproductive organs at birth, post-menarchal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no cause identified other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).",{"count":421,"type":24},100,[423],"PHASE1","Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.",[28,270,274,200,426,202,203],"Acute Migraine","2026-06-20",{"date":334,"type":38},{"date":142,"type":24},{"date":431,"type":24},"2027-08",{"name":433,"class":45},"University of South Florida",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":18,"sex":53,"minAge":440,"maxAge":76,"enrollmentInfo":441,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":46},"100490713","nimh-rhythms-and-blues-study-a-prospective-natural-history-study-of-motor-activity-mood-states-and-bipolar-disorder-100490713","NCT05669703","NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder","* INCLUSION CRITERIA:\n\nTo be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Stated willingness to comply with all study procedures and availability for the duration of the study\n2. Aged 8 and older\n3. Probands must have at least one first-degree relative agree to participate\n4. Affected probands must have a lifetime history of a mood disorder\n5. Unaffected probands must have no lifetime history of a mood disorder\n6. In good general health as evidenced by medical history\n7. Agreement to adhere to Lifestyle Considerations throughout study duration\n8. Ability of subject (or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document.\n\nEXCLUSION CRITERIA:\n\nThe presence of certain medical conditions may interfere with the interpretation or increase risk of medical complications of the assessments including exercise. Therefore, an individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Pregnancy\n2. People in acute episodes of mania or depression (not excluded, but will delay study entry until sufficiently managed to allow participation in study procedures).","8 Years",{"count":442,"type":24},1260,"Background:\n\nMood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances. In this natural history study, researchers would like to learn more about the connection between exercise and mental health in people with and without mood disorders.\n\nObjective:\n\nTo better understand relationships among physical activity, sleep, and mental health.\n\nEligibility:\n\nPeople aged 8 to 60 years with a history of a mood disorder. Healthy spouses and relatives with no mood disorders are also needed.\n\nDesign:\n\nParticipants will be in the study up to 2 years.\n\nFor up to 20 days in a row, at 4 times during the study, participants will:\n\nComplete an electronic diary on their smartphone. Participants will answer questions about their mood, health, sleep, and daily activities.\n\nWear an activity monitor, like a wristwatch, that records how much they move.\n\nWear a light sensor, as a necklace, to record the amount of light in their environment.\n\nSome participants will do additional tests. Twice during the study, for 3 days in a row, they will:\n\nWear monitors to record their temperature, heart rate, and sleep.\n\nProvide saliva samples.\n\nComplete cognitive tasks on their smartphone.\n\nParticipants will visit the NIH clinic 2 times. They will have a physical exam, with blood and urine tests. They will wear a heart monitor. They will ride a stationary bike for 30 minutes. They may have an imaging scan.\n\nSome participants will stay overnight. They will go to sleep wearing a cap to measure their brain activity.",[445,446,28],"Bipolar Disorder","Major Depression",[448,449,450,451,452,453],"Mood Disorders","Actigraphy","CIRCADIAN RHYTHMS","Sleep","Ecological Momentary Assessments","Natural History","2026-06-18",{"date":456,"type":38},"2026-06-22",{"date":458,"type":38},"2023-11-03",{"date":460,"type":24},"2026-07-31",{"name":462,"class":463},"National Institute of Mental Health (NIMH)","NIH",{"id":465,"slug":466,"hasResults":12,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":470,"eligibilityCriteria":471,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":262,"enrollmentInfo":472,"targetDuration":473,"studyType":25,"phases":4,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":485,"completionDateStruct":486,"leadSponsor":488,"locationsCount":46},"100641202","embrace-obs-single-site-observational-registry-of-patient-reported-outcomes-following-mma-embolization-for-migraine-100641202","NCT07652034","EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine","Enduring Migraine Benefit From Responsive Artery Coil Embolization - Observational (EMBRACE-OBS): A Single-Site Registry of Patient-Reported Outcomes Following Routine Clinical Care for Migraine","EMBRACE-OBS","Inclusion Criteria:\n\n* Adults aged 18 to 64 years\n* Diagnosis of migraine\n* Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation\n* Able and willing to provide informed consent\n* Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n\nExclusion Criteria:\n\n* Age under 18 years\n* Pregnancy at the time of enrollment\n* Inability to provide informed consent\n* Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments\n* Insufficient clinical or patient-reported outcome data for the planned analyses",{"count":78,"type":24},"12 Months","EMBRACE-OBS is the first phase of the EMBRACE research program. This single-site observational registry accesses and analyzes patient-reported outcome data already collected through routine clinical care from adults with migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization. The study describes changes in headache frequency, headache severity, medication use, migraine-related disability, quality of life, and reported adverse events over time without influencing clinical care.",[201,279,28],[477,478,28,205,479,480,481,482,470],"Middle Meningeal Artery Embolization","MMA Embolization","Patient-Reported Outcomes","HIT-6","Observational Registry","Neurointervention","2026-06-16",{"date":454,"type":38},{"date":247,"type":24},{"date":487,"type":24},"2028-06-01",{"name":489,"class":147},"Cortex Neurovascular",{"id":491,"slug":492,"hasResults":12,"nctId":493,"briefTitle":494,"officialTitle":495,"acronym":496,"eligibilityCriteria":497,"healthyVolunteers":12,"sex":53,"minAge":498,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":501,"conditions":502,"keywords":505,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":509,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":515},"100562468","post-marketing-study-to-assess-the-safety-and-effectiveness-of-oral-atogepant-in-korean-adult-participants-for-the-prevention-of-chronic-or-episodic-migraine-100562468","NCT06603558","Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine","Post-marketing Surveillance Study to Evaluate the Safety and Effectiveness of Atogepant for the Prevention of Migraine in Korean Adult Patients","Atogepant PMSS","Inclusion Criteria:\n\n* Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.\n* Participants prescribed atogepant in accordance with the approved local label.\n\nExclusion Criteria:\n\n* Participants with any contraindication to atogepant as listed on the latest approved local label.\n* Participants currently participating in another clinical research except observational study.","19 Years",{"count":500,"type":24},3000,"Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and\u002For sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.\n\nAtogepant is an approved drug for preventive treatment of migraine in adults. Approximately 3000 adult participants who are prescribed atogepant by their doctors will be enrolled in this study in Korea.\n\nParticipants will receive atogepant oral tablets as prescribed by their physician. Participants will be followed for up to week 12.\n\nThere is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.",[503,504,28],"Chronic Migraine","Episodic Migraine",[503,504,28,506,507,508],"Atogepant","Qulipta","Aquipta",{"date":454,"type":38},{"date":511,"type":38},"2024-09-24",{"date":513,"type":24},"2029-05",{"name":313,"class":147},4,{"id":517,"slug":518,"hasResults":12,"nctId":519,"briefTitle":520,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":157,"enrollmentInfo":523,"targetDuration":4,"studyType":58,"phases":525,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":539},"100642292","phase-2-study-evaluating-the-efficacy-safety-and-tolerability-of-asy202-dihydroergotamine-mesylate-dhe-inhalation-powder-delivered-via-a-multidose-dry-powder-inhaler-for-the-acute-treatment-of-migraine-in-adult-patients-100642292","NCT07646613","Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients","A Randomized, Double-blind, Placebo-controlled, Crossover, Multi-center Clinical Trial for the Evaluation of Efficacy, Safety, and Tolerability of ASY202 for the Acute Treatment of Migraine in Adult Patients","Inclusion Criteria:\n\n* Able to understand study procedures and provide written informed consent\n* Male or female, 18-65 years of age at Screening\n* BMI between 18.5-35 kg\u002Fm² at Screening\n* Documented history of migraine (with or without aura) for ≥1 year, consistent with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)\n* Female participants must be either:\n\n  * of non-childbearing potential, or\n  * of childbearing potential using protocol required contraception\n\nExclusion Criteria:\n\n* Diagnosis of headache conditions other than migraine\n* History or current diagnosis of coronary artery disease (CAD)\n* History or current diagnosis of coronary artery vasospasm (including Printz-metal's angina), clinically significant arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation) or peripheral vascular disease, ischemic disease (e.g., Raynaud's syndrome, ischemic bowel syndrome, angina pectoris, myocardial infarction, or documented silent ischemia)\n* History of percutaneous coronary intervention, cardiac surgery, sepsis or vascular surgery\n* History or current diagnosis of cerebrovascular disease, including but not limited to stroke, transient ischemic attack, cerebral hemorrhage, or subarachnoid hemorrhage\n* Known history or current diagnosis of psychological and\u002For psychiatric condition that, in the opinion of the Investigator, might interfere with study participation and assessments or participant safety. These conditions may include depression, psychosis, schizophrenia, bipolar disorder, dementia, alcoholism, drug abuse, etc.\n* Known allergic reactions, hypersensitivity, or contraindications to DHE, other ergot-derived products, or any other excipient in the formulation\n* Use of strong or moderate CYP3A4 inhibitors within 14 days (or 5 half-lives) or CYP3A4 inducers within 28 days (or 5 half-lives) prior to Randomization\n* Any clinically significant symptoms or conditions at screening, other than migraine, including but not limited to central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic, or gastrointestinal conditions, or history of such conditions that in the opinion of the Investigator, might interfere with study assessments or participant safety",{"count":524,"type":24},108,[266],"This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it. Adults with migraine will receive both the study medication (ASY202) and a placebo (inactive treatment) at different times during the study. Neither participants nor study staff will know which treatment is given at the time. The medication is taken using a handheld dry powder inhaler to treat migraine attacks when they occur.\n\nFollowing screening, eligible participants will be enrolled and randomized to one of two treatments sequences i.e. one treatment sequence will receive ASY202 in treatment period 1 followed by placebo in treatment period 2 and other treatment sequence will receive placebo in treatment period 1 followed by ASY202 in treatment period 2.\n\nThe study lasts about 16 weeks and includes a screening period, two treatment periods (with a minimum of 7 days washout period between the treatment periods), and a safety follow-up visit.",[28],[28,529,530],"DHE","Dihydroergotamine Mesylate","2026-06-15",{"date":483,"type":38},{"date":534,"type":38},"2026-05-19",{"date":536,"type":24},"2026-12",{"name":538,"class":147},"Aspeya, Inc.",3,{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":58,"phases":549,"briefSummary":550,"conditions":551,"keywords":555,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":563,"leadSponsor":565,"locationsCount":4},"100641779","phase-4-comparing-migraine-preventive-therapies-vs-anti-cgrp-therapies-for-tinnitus-in-patients-with-migraine-compact-pm-100641779","NCT07655440","Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM)","Comparative Outcomes of Migraine Preventives and Anti-CGRP Therapies for Tinnitus in Patients With Migraine: A Randomized Active-Comparator Controlled Trial (COMPACT-PM)","COMPACT-PM","Inclusion Criteria:\n\n* Age 18 years or older\n* Non-pulsatile, subjective tinnitus present for at least 6 months\n* Tinnitus Functional Index (TFI) score greater than 25 at screening, indicating at least mild-to-moderate tinnitus burden\n* Current or past history of migraine, vestibular migraine, or episodic headache disorder, diagnosed by a physician or meeting ICHD-3 criteria\n* Clinically appropriate candidate for migraine preventive therapy as determined by the treating clinician\n* Stable medication regimen for at least 3 months prior to enrollment (no new medications started or stopped within 3 months of screening)\n* Ability to provide written informed consent\n* Ability to complete self-report questionnaires in English or with certified interpreter assistance\n* Willingness to attend three in-person study visits over 24 weeks and complete daily symptom diaries\n\nExclusion Criteria:\n\n* Pulsatile tinnitus or objective tinnitus (tinnitus audible to examiner)\n* Pregnancy, planned pregnancy during the study period, or breastfeeding\n* Participation in any other interventional tinnitus treatment research protocol during the study period\n* Currently receiving a CGRP-targeting medication (for participants being considered for the conventional arm) or a conventional migraine preventive medication listed in this protocol (for participants being considered for the CGRP arm) - to avoid within-arm ineligibility at randomization\n* Known contraindication to all medications within the assigned study arm\n* History of serious cardiovascular event (myocardial infarction, stroke, or unstable angina) within 6 months of enrollment\n* Severe hepatic or renal impairment that would contraindicate study medications\n* Active psychiatric disorder requiring medication adjustment within 3 months of enrollment\n* Known hypersensitivity or prior serious adverse reaction to a medication within the assigned study arm\n* Active malignancy or life expectancy less than 12 months\n* Inability to complete study procedures or follow-up visits in the judgment of the investigator",{"count":23,"type":24},[377],"Many people with migraine also experience tinnitus - a persistent ringing, buzzing, or hissing in the ears - and research suggests these conditions share underlying biological mechanisms, including a protein called calcitonin gene-related peptide (CGRP) that is active in both the brain and the inner ear. COMPACT-PM is a randomized trial comparing two classes of migraine preventive medications in adults with bothersome tinnitus and a history of migraine: anti-CGRP therapies (newer injectable or oral agents that block CGRP or its receptor) versus conventional migraine preventives (antidepressants including amitriptyline, nortriptyline, and venlafaxine; antihypertensives including propranolol, verapamil, and candesartan; and the anticonvulsant topiramate). Participants are randomly assigned - like a coin flip - to one of the two treatment groups; neither group receives a placebo, as both receive active migraine treatment. The study's primary outcome is change in the Tinnitus Functional Index (TFI) over 24 weeks, with additional measures including hearing tests, balance assessments, auditory brainstem response testing, and a comprehensive symptom diary. The study is conducted at the Stanford Ear Institute and is funded by a philanthropic gift to the Department of Otolaryngology - Head \\& Neck Surgery at Stanford University.",[552,553,28,554],"Migraine Associated Vertigo","Tinnitus","Vestibular Migraine",[556,112,557,558,559],"tinnitus","vestibular migraine","migraine-associated tinnitus","CGRP",{"date":561,"type":38},"2026-06-17",{"date":142,"type":24},{"date":564,"type":24},"2031-07",{"name":566,"class":45},"Stanford University",{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":18,"sex":53,"minAge":106,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":25,"phases":4,"briefSummary":576,"conditions":577,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":46},"100641349","scapular-muscle-activation-and-shoulder-performance-in-migraine-100641349","NCT07656922","Scapular Muscle Activation and Shoulder Performance in Migraine","INVESTIGATION OF SCAPULAR MUSCLE ACTIVATION AND SHOULDER PERFORMANCE IN INDIVIDUALS WITH MIGRAINE","Inclusion Criteria:\n\n* Aged 18-55 years\n* Diagnosed with migraine by a neurologist according to the ICHD-3 criteria\n* Experiencing at least 3 migraine attacks per month\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of other types of headache disorders\n* History of trauma, fracture, or surgery involving the cranio-cervical region, scapular region, or upper extremity\n* Presence of neurological or inflammatory rheumatic diseases\n* Presence of psychiatric disorders\n* Receiving physiotherapy or rehabilitation for migraine or the cervical, thoracic, or upper extremity regions within the past 6 months\n* Cognitive impairment affecting the understanding of test instructions","55 Years",{"count":78,"type":24},"Migraine is a significant health problem due to its high prevalence and substantial contribution to disability. Individuals with migraine have been reported to exhibit myofascial trigger points, increased pain sensitivity, and altered muscle activation patterns, particularly in the trapezius muscles. As the upper and middle trapezius muscles play critical roles in scapular stability and movement, alterations in these muscles may affect scapular orientation and upper extremity function. However, studies investigating the relationship between trapezius muscle activation, scapular orientation, and upper extremity performance in individuals with migraine are limited. Therefore, this study aimed to compare trapezius muscle activation, scapular orientation, and upper extremity performance between individuals with and without migraine. We hypothesized that individuals with migraine would exhibit altered upper and middle trapezius muscle activation, impaired scapular orientation, and reduced upper extremity performance compared with healthy controls.",[28,578,579],"Upper Extremity","Muscle Activity",{"date":454,"type":38},{"date":582,"type":38},"2026-04-01",{"date":584,"type":24},"2026-07-15",{"name":586,"class":45},"Ankara Yildirim Beyazıt University",{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":591,"acronym":4,"eligibilityCriteria":592,"healthyVolunteers":12,"sex":53,"minAge":54,"maxAge":232,"enrollmentInfo":593,"targetDuration":4,"studyType":58,"phases":595,"briefSummary":596,"conditions":597,"keywords":600,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":613,"leadSponsor":615,"locationsCount":617},"100417438","mind-body-balance-for-pediatric-migraine-100417438","NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study",{"count":594,"type":24},260,[60],"This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[205,598,599,28,201,203,202,503],"Headache Disorders","Headache, Migraine",[164,112,601,602,603,604,605,606,607,608],"cognitive behavioral therapy","pediatrics","mind body intervention","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","2026-06-14",{"date":483,"type":38},{"date":612,"type":38},"2021-03-09",{"date":614,"type":24},"2026-11-30",{"name":616,"class":45},"Children's Hospital Medical Center, Cincinnati",2,{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":4,"eligibilityCriteria":624,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":574,"enrollmentInfo":625,"targetDuration":4,"studyType":58,"phases":626,"briefSummary":627,"conditions":628,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":629,"lastUpdatePostDateStruct":630,"startDateStruct":631,"completionDateStruct":633,"leadSponsor":634,"locationsCount":46},"100641327","the-effects-of-physiotherapy-in-migraine-100641327","NCT07657377","The Effects of Physiotherapy in Migraine","The Effects of Physiotherapy Applications in Individuals With Migraine","Inclusion Criteria:\n\n* Volunteering to participate in the study\n* Being between 18 and 55 years of age\n* Being diagnosed with migraine by a neurologist according to the International Classification of Headache Disorders 3 (ICHD-3) criteria\n\nExclusion Criteria:\n\n* Diagnosis of other primary and\u002For secondary headaches in addition to migraine,\n* Coexisting neurological and\u002For rheumatological diseases,\n* Severe psychiatric disorders (bipolar disorder, schizophrenia, psychosis, etc.),\n* Pregnancy or lactation,\n* Malignancy,\n* Known arrhythmia or presence of any implanted electronic device,\n* Presence of sensory loss in the application area,\n* Having received physiotherapy or any other treatment in the head\u002Fneck region within the last 12 months,\n* History of head\u002Fneck trauma or surgery within the last 12 months.",{"count":78,"type":24},[60],"The aim of this study is to investigate the effects of a physiotherapy program including cervical muscle training and transcutaneous vagus nerve stimulation on pain, functional status, quality of life, psychological status, and sleep quality in individuals with migraine.",[28],"2026-06-13",{"date":454,"type":38},{"date":632,"type":24},"2026-08",{"date":431,"type":24},{"name":586,"class":45},{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":58,"phases":644,"briefSummary":645,"conditions":646,"keywords":647,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":654,"completionDateStruct":655,"leadSponsor":657,"locationsCount":46},"100642224","a-comprehensive-digital-care-program-for-migraine-management-100642224","NCT07642414","A Comprehensive Digital Care Program for Migraine Management","Evaluation of a Comprehensive Digital Care Program for Migraine: A Prospective, Single-Arm, Pilot Study","Inclusion Criteria:\n\n* 18 years of age or older\n* Documented or clinical history of episodic or chronic migraine (with or without aura) for at least 12 months, consistent with ICHD-3 criteria. Verification of diagnosis must be established using one or more of the following methods: participant-provided medical records, documented pharmacy prescription history, or validated diagnostic screening instruments.\n* Passes ID-Migraine Screener with a score of 2 or more \"yes\" answers to the following question: During the last 3 months, did you experience any of the following with your migraines? (1) Your migraines limited your ability to complete your daily activities for more than one day; (2) You felt nauseated or sick to your stomach; (3) Light bothered you (a lot more than when you don't have migraines).\n* Migraine onset occurred at age 50 years or younger\n* Minimum of 4 migraine days during the 28-day baseline run-in period, as confirmed by the study eDiary\n* At least 80% eDiary compliance (minimum of 22 out of 28 days) during the prospective baseline run-in period\n* Currently on a stable dose of traditional oral migraine preventive medication (e.g., topiramate, beta-blockers, amitriptyline) for at least 90 days prior to the start of the 28-day baseline period, or taking no preventive medication\n* Currently on a stable dose of CGRP monoclonal antibodies (e.g., Aimovig, Emgality, Ajovy, Vyepti) or OnabotulinumtoxinA (Botox) for at least 180 days (6 months) prior to the start of the 28-day baseline period\n* Willingness to maintain current preventive and as-needed (acute) medication regimens (e.g., triptans, NSAIDs, or abortive gepants) and refrain from initiating any brand new pharmacological or clinical treatments (e.g., nerve blocks, Botox, or infusions) for the duration of the 12-week intervention period\n* Sufficient physical mobility to engage with the exercise therapy component of the program, with or without reasonable accommodations; participants reporting significant mobility restrictions (e.g., wheelchair use) will be eligible pending a clinical safety review by a Study Physician or Physical Therapist\n* Active commercial health insurance coverage (either as the primary policyholder or a covered dependent) through an employer-sponsored health plan, commercial health insurer, or an affiliated benefit partner eligible for digital health solution deployment\n* US resident\n* Has a valid email account\n* Personal ownership of a smartphone (iOS 15 or later, or Android 10 or later) with Bluetooth capability, app store access, and compatibility with the eDiary\n* Able to understand and provide voluntary informed consent\n\nExclusion Criteria:\n\n* Presence of a cardiac pacemaker, implanted or wearable defibrillator, spinal cord stimulator, pain pump, insulin pump, or any other active implanted electronic medical device\n* Presence of a metal implant in the head or neck (excluding dental work)\n* Supraorbital nerve blocks or infusion treatments for migraine received within 4 months before the start of the baseline period\n* Presence of other primary or secondary headache disorders (e.g., cluster headache, New Daily Persistent Headache, or post-traumatic headache); Note: Medication Overuse Headache (MOH) is NOT an exclusion criterion\n* History of major head or neck injuries or any physical condition (e.g., severe cervical spine instability) that, in the opinion of the Principal Investigator and\u002For Study Physician, would make the exercise therapy component of the program unsafe; History of major cardiovascular events (e.g., stroke, arrhythmia, myocardial infarction)\n* History of major migraine complications (e.g., migrainous infarction or aura-triggered seizure)\n* Presence of fever, chills, or night sweats lasting five or more days and not improving\n* Significant change in headache pattern, including headaches that are becoming much more severe or frequent, represent a new type of pain, wake the participant from sleep, or worsen with positional changes (e.g., coughing, bearing down, or changing position)\n* Recent changes in vision, mental status, sensation, or strength; or new onset of jaw pain or neck stiffness\n* Unexplained significant weight loss (past 3 months), or persistent weakness\u002Fnumbness in the extremities (past 3 months)\n* Known history of conditions that may compromise the immune system\n* Head trauma within the past 2 weeks or diagnosis of a spinal fracture or shoulder dislocation within the past 3 months\n* Any major trauma, fracture, or significant injury (e.g., car accident, sports injury) within the past 3 months\n* Any major surgery within the past 3 months\n* Inability to stand up from a chair without assistance (unless the participant utilizes a wheelchair and has been cleared via PT review)\n* History of falling due to balance, weakness, vision, or other physical limitations within the past 3 months\n* Current diagnosis of epilepsy or active malignancy (history of cancer within the last 5 years)\n* Presence of a cognitive or neurological disorder (e.g., dementia, Parkinson's disease) that may interfere with study participation\n* Currently unmanaged psychiatric disorder (e.g., schizophrenia, substance abuse, or severe major depressive disorder\u002Fanxiety) that, in the opinion of the investigator, could prevent compliance with study instructions\n* Pregnant, planning to become pregnant during the study, or currently breastfeeding\n* Currently institutionalized\n* Insufficient proficiency with the English language to take part in study procedures or complete online surveys\n* Current or previous enrollment in any Hinge Health Program or participation in prior Hinge Health research studies\n* Current ownership or previous use of an Enso device or other prescribed high-frequency electrical stimulation therapy for the treatment of pain\n* Participation in an investigational study within 30 days prior to screening\n* Planned travel outside of the U.S. within the first month of enrollment\n* Current employees or contractors of Hinge Health, Inc. or L\\&E Research, and their immediate family members",{"count":643,"type":24},140,[60],"This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a dedicated care team, in reducing migraine frequency among adults with episodic or chronic migraine.",[28,203,202],[112,648,649,650,651],"transcutaneous electrical nerve stimulation","neuromodulation","digital health","exercise therapy","2026-06-12",{"date":483,"type":38},{"date":283,"type":24},{"date":656,"type":24},"2026-11",{"name":658,"class":147},"Hinge Health, Inc",{"id":660,"slug":661,"hasResults":12,"nctId":662,"briefTitle":663,"officialTitle":664,"acronym":665,"eligibilityCriteria":666,"healthyVolunteers":12,"sex":53,"minAge":106,"maxAge":4,"enrollmentInfo":667,"targetDuration":4,"studyType":58,"phases":669,"briefSummary":670,"conditions":671,"keywords":672,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":674,"startDateStruct":675,"completionDateStruct":676,"leadSponsor":678,"locationsCount":46},"100529169","sequential-multiple-assignment-double-randomized-preference-migraine-behavioral-trial-100529169","NCT06170281","Sequential, Multiple Assignment, Double Randomized Preference, Migraine Behavioral Trial","A Feasibility Clinical Trial Assessing Patient Preference, Optimum Combinations and Sequences of a Multicomponent, Virtually-Delivered Migraine Behavioral Intervention","SMARTMig","Inclusion Criteria:\n\n* have chronic migraine for a minimum of 1-year\n* aged 18 years and older\n\nExclusion Criteria:\n\n* secondary headache disorders\n* children younger than 18 years old",{"count":668,"type":24},24,[60],"This study will unpack the behavioral intervention for migraine and determine the optimum combinations. In addition, the study will test preference and self-selection effects during the trial.",[28,205,503,598],[112,164,673],"behavioral intervention",{"date":483,"type":38},{"date":536,"type":24},{"date":677,"type":24},"2028-12-01",{"name":388,"class":45}]